AQR Capital Management’s Dyne Therapeutics DYN Stock Holding History

AQR Capital Management’s Portfolio DYN Stock Details DYN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.53M	Buy	84,238 +13,579	+19%	+$234K	﹤0.01%	2529
2025 Q4	$1.38M	Sell	70,659 -71,216	-50%	-$1.35M	﹤0.01%	2367
2025 Q3	$1.79M	Buy	141,875 +98,965	+231%	+$1.13M	﹤0.01%	2038
2025 Q2	$409K	Buy	42,910 +19,350	+82%	+$213K	﹤0.01%	2718
2025 Q1	$246K	Buy	+23,560	New	+$337K	﹤0.01%	2781
2024 Q4	–	Sell	-89,198	Closed	-$3.2M	–	2891
2024 Q3	$3.2M	Buy	89,198 +80,703	+950%	+$3.21M	﹤0.01%	1262
2024 Q2	$300K	Buy	8,495 +352	+4%	+$10.2K	﹤0.01%	2268
2024 Q1	$231K	Buy	+8,143	New	+$184K	﹤0.01%	2219
2023 Q4	–	Sell	-11,644	Closed	-$104K	–	2354
2023 Q3	$104K	Sell	11,644 -8,525	-42%	-$91.8K	﹤0.01%	2226
2023 Q2	$227K	Buy	+20,169	New	+$238K	﹤0.01%	2047

Other funds holding DYN

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

AQR Capital Management's DYN Position: Q1 2026 in Review

AQR Capital Management increased its Dyne Therapeutics (DYN) stake by 19% in Q1 2026, buying an estimated $234K and bringing the position to 84,238 shares worth $1.53M. The position accounts for ﹤0.01% of the portfolio, ranked #2529.

AQR Capital Management first reported a position in DYN in Q2 2023 and has held it in 10 quarters since. The position peaked at $3.2M in Q3 2024. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

AQR Capital Management held 84,238 shares of Dyne Therapeutics worth $1.53M as of Q1 2026.
AQR Capital Management bought 13,579 Dyne Therapeutics shares in Q1 2026, an estimated $234K.
Dyne Therapeutics made up ﹤0.01% of AQR Capital Management's portfolio in Q1 2026, its #2529 holding.
AQR Capital Management first reported a position in Dyne Therapeutics in Q2 2023 and has held it in 10 quarters since.
AQR Capital Management's Dyne Therapeutics position peaked at $3.2M in Q3 2024.
227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on AQR Capital Management's 13F filing for Q1 2026, filed 15 May 2026.